Patent · US Active

IFN beta protein analogs

US11242372B2 · kind B2 · utility

0Cited by
1References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 30, 2018
Grant dateFeb 8, 2022
Priority date
Expiry dateOct 3, 2040

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides a composition comprising an interferon-beta (IFN-beta) protein of which at least 80% is deamidated, a deamidated IFN-beta 1a protein, methods of producing deamidated proteins, and therapeutic uses of such compositions and deamidated IFN-beta 1a proteins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.